DFW Capital Partners has completed the sale Metanexgen, a marketing services company serving the life sciences industry, to Insignia Capital Group.
DFW acquired Meta Pharmaceutical Services, a provider of data-driven email and direct mail marketing services, from its founders in August 2010. In June 2013 the company merged with NexGen RxMarketing, a provider of online video and virtual meeting marketing services. The combined company was renamed Metanexgen. Today, Metanexgen is a provider of data-driven multi-channel marketing services that are used by pharmaceutical, biotechnology and medical device brands to market their products to healthcare practitioners. Metanexgen is headquartered near Philadelphia in Bensalem, PA (www.metanexgen.com).
“We have been fortunate to partner with the deeply talented and committed Metanexgen management team. It has been a pleasure to work with the team as the organization developed and delivered significant growth, resulting in a great outcome for our investors,” said Brian Tilley, a Partner at DFW.
DFW Capital Partners invests in lower middle-market service companies, with an emphasis on healthcare and outsourced business and industrial support services. DFW is headquartered in Teaneck, NJ, and maintains an office in Washington, DC (www.dfwcapital.com).
“Reduced access to healthcare practitioners is driving pharmaceutical, biotechnology and medical device companies to spend more on multi-channel marketing services,” said Tony Broglio, a Partner at Insignia. “We believe Metanexgen’s full-service offering and technology solutions position the company at the forefront of the multi-channel marketing sector.”
Insignia Capital Group invests in lower middle-market companies with revenues of at least $20 million. The firm will consider investments in an array of industries but has a specific interest in consumer, business services and healthcare. Insignia Capital Group is based near San Francisco in Walnut Creek (www.insigniacap.com).
“We have enjoyed and sincerely appreciate our partnership with DFW. Their support, vision, and guidance has helped position Metanexgen as a market leader that is well prepared to meet our clients’ growing needs, expand our offerings, and accelerate growth,” said Chris Wiltshire, Metanexgen’s President and CEO. “We look forward to partnering with Insignia as we work to deliver extraordinary outcomes for our clients, employees, and shareholders.”
Lazard Middle Market (www.lazardmm.com) served as the exclusive financial advisor to Metanexgen.
© 2015 PEPD • Private Equity’s Leading News Magazine • 4-22-15
